more

Accuray (ARAY)

(Delayed Data from NSDQ)

$2.09 USD

+0.06 (2.96%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $2.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

Top 25% (63 out of 251)

Industry: Medical - Instruments

View All Zacks #1 Ranked Stocks

Zacks News

Here's Why You Should Hold on to CONMED (CNMD) Stock Now

by Zacks Equity Research Published on March 12,2020

CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and persistent focus on R&D. However, forex remains a woe.

medical

Masimo Inks Deal With Imprivata, Improves Patient Monitoring

by Zacks Equity Research Published on March 11,2020

Masimo's (MASI) partnership with Imprivata is likely to boost patient outcomes through the integration of Imprivata Medical Device Access into Masimo's Hospital Automation solutions.

medical

Here's Why You Should Retain HMS Holdings (HMSY) Stock Now

by Zacks Equity Research Published on March 11,2020

HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services.

medical

Is Accuray (ARAY) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research Published on March 06,2020

Is (ARAY) Outperforming Other Medical Stocks This Year?

ARAYPositive Net Change

Cooper Companies (COO) Misses on Q1 Earnings, Lifts View

by Zacks Equity Research Published on March 06,2020

Cooper Companies (COO) gains from core CVI segment in fiscal Q1.

Here's Why You Should Invest in Intuitive Surgical Stock Now

by Zacks Equity Research Published on March 06,2020

Intuitive Surgical (ISRG) continues to benefit from da Vinci surgical system, strong global foothold and solid recurring revenue base. However, stiff competition remains a woe.

medical

Here's Why You Should Hold on to OPKO Health Stock for Now

by Zacks Equity Research Published on March 05,2020

OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and focus on R&D despite operating losses.

medical

Allscripts (MDRX) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research Published on March 04,2020

Allscripts (MDRX) fourth-quarter results gain from higher revenues along with growth in bookings. Contraction in both gross and operating margins remains a woe.